Show Summary Details
Page of

(p. 545) Treatments for Obsessive-Compulsive Disorder 

(p. 545) Treatments for Obsessive-Compulsive Disorder
(p. 545) Treatments for Obsessive-Compulsive Disorder

Darin D. Dougherty

, Scott L. Rauch

, and Michael A. Jenike

Page of

PRINTED FROM OXFORD CLINICAL PSYCHOLOGY ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Clinical Psychology Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 October 2020

There is overwhelming evidence of the most rigorous type supporting the efficacy of serotonin reuptake inhibitors (SRIs) in the treatment of obsessive-compulsive disorder (OCD). Along with SRIs, behavior therapy must be considered a viable first-line therapy. The best available data suggest that behavior therapy, and perhaps cognitive therapy, is at least as effective as medication in some instances and may be superior with respect to risks, costs, and enduring benefits. A variety of second-line medication treatments for OCD have been studied in a controlled or systematic fashion. Augmentation of SRIs with antipsychotics, buspirone, or clonazepam is provisionally recommended based on the available data. Other monotherapies and augmentation strategies find very limited support at present.

Access to the complete content on Oxford Clinical Psychology requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.